Navigation Links
Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
Date:5/24/2012

PITTSBURGH, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product.

The U.S. District Court for the Southern District of New York's Final Judgment and Order notes that the parties have entered into a settlement and license agreement and that Sunovion has acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana® product. These patents expire on June 22, 2021. The terms of the parties' agreement are confidential.

Mylan CEO Heather Bresch commented, "We are pleased with this settlement and remain confident in the intellectual property protecting Perforomist®, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease (COPD), currently in development. We believe this settlement and judgment by the Court further strengthen the potential of our Specialty franchise and its portfolio of products."

Mylan intends to appeal the judgment concerning other Mylan patents that were litigated.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement of the litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product sales; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
2. Mylan Launches Generic Version of Viramune® Tablets
3. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
4. Mylan Launches Generic Version of Plavix® Tablets
5. Mylan Launches Generic Lipitor® in Five European Countries
6. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
7. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
8. Mylan Launches Generic Version of Zyprexa® Tablets
9. Mylan Launches First Generic Version of Lescol® Capsules
10. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
11. Mylan One of First to Launch Generic Version of Boniva®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 This morning,s ... four stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood ... PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: ... Drugs space which is governed by the same ... for the industry are wholesalers, retailers, pharmacies, and ...
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... The global surgical sealants ... of USD 4.5 billion by 2025, according to a ... of injured tissues post operation is a major step ... in 3% to 15% of cases and are considered ... third of postoperative deaths in patients. Surgical sealants and ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a ... time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service ... uses biometric face recognition to enable users to check in and out from ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... The ... in Atlantic City March 13-16, was a busy spot this year. Liz Solovay ... discussed strategies for preventing outbreaks among camp communities during the upcoming 2017 camping ...
(Date:3/28/2017)... MO (PRWEB) , ... March 28, 2017 , ... ... of job satisfaction in their profession as their value increases in the healthcare ... that provides resources such as job boards, career fairs, and candidate leads to ...
(Date:3/27/2017)... Eau Claire, WI (PRWEB) , ... March 27, ... ... currently accepting new patients for custom smile makeovers without requiring a ... needs including orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients ...
Breaking Medicine News(10 mins):